Telesis Bio Inc. (TBIO)
Telesis Bio Statistics
Share Statistics
Telesis Bio has 1.78M shares outstanding. The number of shares has increased by -94.08% in one year.
Shares Outstanding | 1.78M |
Shares Change (YoY) | -94.08% |
Shares Change (QoQ) | 0.16% |
Owned by Institutions (%) | 36.29% |
Shares Floating | 1.34M |
Failed to Deliver (FTD) Shares | 255 |
FTD / Avg. Volume | 6.89% |
Short Selling Information
The latest short interest is 29.7K, so 1.67% of the outstanding shares have been sold short.
Short Interest | 29.7K |
Short % of Shares Out | 1.67% |
Short % of Float | 2.21% |
Short Ratio (days to cover) | 0.42 |
Valuation Ratios
The PE ratio is -4.49 and the forward PE ratio is -0.01. Telesis Bio's PEG ratio is 7.41.
PE Ratio | -4.49 |
Forward PE | -0.01 |
PS Ratio | 7.79 |
Forward PS | 0.1 |
PB Ratio | 7.26 |
P/FCF Ratio | -5.85 |
PEG Ratio | 7.41 |
Enterprise Valuation
Telesis Bio Inc. has an Enterprise Value (EV) of 44.55M.
EV / Earnings | -0.93 |
EV / Sales | 1.62 |
EV / EBITDA | -1.1 |
EV / EBIT | -0.96 |
EV / FCF | -1.22 |
Financial Position
The company has a current ratio of 3.71, with a Debt / Equity ratio of 1.16.
Current Ratio | 3.71 |
Quick Ratio | 3.22 |
Debt / Equity | 1.16 |
Total Debt / Capitalization | 53.79 |
Cash Flow / Debt | -1.01 |
Interest Coverage | -14.99 |
Financial Efficiency
Return on equity (ROE) is -1.62% and return on capital (ROIC) is -72.85%.
Return on Equity (ROE) | -1.62% |
Return on Assets (ROA) | -0.68% |
Return on Capital (ROIC) | -72.85% |
Revenue Per Employee | $705,358.97 |
Profits Per Employee | $-1,223,692.31 |
Employee Count | 39 |
Asset Turnover | 0.39 |
Inventory Turnover | 2.62 |
Taxes
Income Tax | 24K |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -96.34% in the last 52 weeks. The beta is 1.63, so Telesis Bio's price volatility has been higher than the market average.
Beta | 1.63 |
52-Week Price Change | -96.34% |
50-Day Moving Average | 0.35 |
200-Day Moving Average | 1.9 |
Relative Strength Index (RSI) | 41.57 |
Average Volume (20 Days) | 3.7K |
Income Statement
In the last 12 months, Telesis Bio had revenue of 27.51M and earned -47.72M in profits. Earnings per share was -1.64.
Revenue | 27.51M |
Gross Profit | 16.95M |
Operating Income | -46.54M |
Net Income | -47.72M |
EBITDA | -40.49M |
EBIT | -46.54M |
Earnings Per Share (EPS) | -1.64 |
Balance Sheet
The company has 1.57M in cash and 34.38M in debt, giving a net cash position of -32.81M.
Cash & Cash Equivalents | 1.57M |
Total Debt | 34.38M |
Net Cash | -32.81M |
Retained Earnings | -161.47M |
Total Assets | 24.74M |
Working Capital | 1.49M |
Cash Flow
In the last 12 months, operating cash flow was -34.67M and capital expenditures -1.98M, giving a free cash flow of -36.65M.
Operating Cash Flow | -34.67M |
Capital Expenditures | -1.98M |
Free Cash Flow | -36.65M |
FCF Per Share | -1.23 |
Margins
Gross margin is 61.62%, with operating and profit margins of -169.18% and -173.49%.
Gross Margin | 61.62% |
Operating Margin | -169.18% |
Pretax Margin | -173.4% |
Profit Margin | -173.49% |
EBITDA Margin | -147.2% |
EBIT Margin | -169.18% |
FCF Margin | -133.22% |
Dividends & Yields
TBIO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -565.52% |
FCF Yield | -7116.01% |
Analyst Forecast
Currently there are no analyst rating for TBIO.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Stock Splits
The last stock split was on May 9, 2024. It was a backward split with a ratio of 1:18.
Last Split Date | May 9, 2024 |
Split Type | backward |
Split Ratio | 1:18 |
Scores
Altman Z-Score | -14.23 |
Piotroski F-Score | 3 |